GEOVAX LABS INC. GOVX news, videos and press releases
For more news please use our advanced search feature.
GEOVAX LABS INC. GOVX - More news...
GEOVAX LABS INC. GOVX - More news...
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
- GeoVax to Present at the 36th Annual Roth Conference
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
- GeoVax to Present at the 2024 BIO CEO & Investor Conference
- GeoVax Announces Multiple Patent Issuances and Allowances
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
- GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
- GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
- GeoVax Announces Issuance of Malaria Vaccine Patent
- GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
- GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
- GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
- GeoVax to Participate in Upcoming December Investor Events
- GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
- Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
- GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
- GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
- GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
- GeoVax to Participate in Upcoming November Investor and Industry Events
- GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
- GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
- GeoVax Receives Notice of Allowance for HIV Vaccine Patent
- GeoVax to Participate in Upcoming October Investor and Industry Events
- GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
- GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
- GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
